Drug Effectiveness Assessment
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Do Larger Models Really Win in Drug Discovery? A Benchmark Assessment of Model Scaling in AI-Driven Molecular Property and Activity Prediction
Announce Type: replace Abstract: The rapid growth of molecular foundation models and large language models (LLMs) has encouraged a scale centred view of AI in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models. We test this assumption across 26 ADME, toxicity and bioactivity endpoints, covering 165,541 endpoint level compound label records. The benchmark contains 78 endpoint and split entries evaluated under random, Murcko scaffold and...
Flu drugs might fight cognitive decline seen in HIV, early study hints
Flu drugs might fight cognitive decline seen in HIV, early study hints A very early study suggests flu antivirals might help reverse certain signs of accelerated aging in people with HIV. But more research is needed to confirm these effects. Flu drugs may help ward off the low-grade inflammation and related cognitive decline that can come with HIV infection, an early study suggests.
UniD$^3$: A Knowledge Graph-Enhanced RAG Framework for Drug-Disease Discovery and Reasoning
Announce Type: new Abstract: Systematic characterization of drug-disease relationships is essential for drug discovery and repurposing, yet is hindered by the heterogeneity and rapid growth of biomedical literature. Existing datasets rely on labor-intensive curation and are often incomplete, while LLM-only approaches suffer from hallucination and weak evidence grounding. We introduce UniD$^3$, a unified framework that integrates Large Language Models with Knowledge Graph-enhanced...
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled as much 32% after it reported fresh data on its lead asset, a drug for ulcerative colitis. The medicine met its endpoints of demonstrating a clinically meaningful efficacy and a remission rate of about 40% for both doses tested, but also showed that there were cancer cases among patients taking the higher dose. "[The] cancer signal complicates matters," a Jefferies analyst said.
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.
Fluorescent nanosensor detects key gut biomarker in minutes for faster testing
Fluorescent nanosensor detects key gut biomarker in minutes for faster testing Sadie Harley Scientific Editor Robert Egan Associate Editor A research collaboration has developed a novel fluorescent nanosensor capable of rapidly detecting indole-3-propionic acid (IPA), an emerging biomarker linked to gut health and disease. The breakthrough is described in the team's paper, "Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring," published in the journal...
Dad’s warning after son, 12, finally gets 'life-changing' Duchenne drug
Dad’s warning after son, 12, finally gets 'life-changing' Duchenne drug The drug givinostat - used for Duchenne Muscular Dystrophy management - remains unavailable to boys and young men who can no longer walk and this had plunged Alex Clarke's family into uncertainty A 12-year-old boy with a rare muscle-wasting condition has finally started a life-changing NHS treatment after years of uncertainty for his family. Ben Clarke has Duchenne Muscular Dystrophy (DMD), a severe, progressive genetic...
RFK Jr’s FDA to study if abortion pill mifepristone is safe despite it being on market for over 25 years: report
RFK Jr’s FDA to study if abortion pill mifepristone is safe despite it being on market for over 25 years: report Roughly 7.5 million women have taken the pill over the past 25 years - Bookmark - CommentsGo to comments The U.S. Food and Drug Administration is reportedly opening up a politically-charged investigation into the safety of the abortion pill mifepristone — a drug long considered to be the gold standard for early medical abortions. The investigation, spurred by conversations with...
Health authorities launch crackdown on illegal peptides, amid surge in use
TGA cracks down on unregulated peptides, says increased imports are posing a risk to consumer safety Wed 10 Jun 2026 at 5:00pm In short: The Therapeutic Goods Administration has named unapproved peptides as a new priority focus area.